That the medicine reaches every hospital and pharmacy

Stada Group, within which Hemofarm operates, has shown that it is resistant to the crisis caused by the coronavirus pandemic around the world - this company in 2020 at the global level, it achieved sales growth of 18 percent and annual sales that at the group level exceed three billion euros. Stada has made significant strides in relation to the stagnant market and has shown the strength to enable a regular supply of medicines to hospitals and patients in difficult times.

"Throughout the past year, our priority has been to ensure the health and safety of our employees and their families." We also responded to the pandemic with agility and continued to strengthen our supply chain. I am proud of how Stada, in the middle of the pandemic, worked tirelessly with hundreds of partners to regularly supply the market with medicines and to fulfill our purpose of taking care of people's health as a reliable partner", commented Stada CEO Peter Goldschmidt.

EBITDA growth-e of 15 percent to EUR 713 million

Successful acquisitions, as well as improved efficiency in the supply chain, procurement, sales and marketing, contributed to an increase in adjusted earnings before interest, taxes and depreciation (EBITDA) by 15 percent to EUR 713 million. "We have achieved sales and profit growth above the market average, and this is the result of great engagement and entrepreneurship of our employees." "Our strategy to position Stada as a partner of choice in the field of consumer health products, pharmaceutical specialties and generic products is succeeding," says Stada's CEO.

What to - one of the five leading players in Europe

During 2020, Stada reached fourth place on the European market of generic products, while on the market of consumer health products it improved its position from ninth to fifth place. Outside of Europe, Stada continued to strengthen its presence in selected Asian markets such as China, the Philippines and Vietnam, as well as in the Middle East and North Africa. Consumer health products and pharmaceutical specialty brands now account for around half of the Group's sales totaling €3,01 billion in 2020. During the last year, the company concluded seven acquisitions and 80 licenses, which increased the number of employees by 1675 new positions to a total of 12.300 workers that Stada employs worldwide.

hemofarm - leader in the region

Hemofarm has been operating within the Štada Group since 2006, and every year it increases its production capacity and the range of medicines and other preparations produced in its facilities. "Last year we confirmed our leadership position in the region with the production of 6,5 billion tablets and other forms. Since we are talking about a year marked, unfortunately, by the still current pandemic, our greatest success is certainly the fact that we produced medicines on time and in the required quantity in our factories in Serbia, Bosnia and Herzegovina and Montenegro and delivered them all over the world. With a personal example, we have shown how important it is for every country and its citizens to have domestic production of medicines", emphasizes the CEO of Hemofarm, Ronald Zeliger.

Optimistic outlook for 2021.

Relying on a clear strategy, the company expects to continue growing in 2021. Stada is considering new acquisitions, licensing and other business development opportunities, and is therefore confident of achieving further growth this year. "As the partner of choice in the field of consumer health products, pharmaceutical specialties and generic products, Štada expands its portfolio and realizes our purpose to take care of people's health as a reliable partner," concluded Goldschmidt.